Cyxone is a resource efficient company
Cyxone is a resource efficient company, built by an international network of specialists, focused on developing substances that inhibit key processes in the body’s cells, which are typical for severe autoimmune diseases. The company focuses on building a diversified development portfolio within autoimmune diseases through a virtually constructed organization, where expertise and leading collaboration partners within their areas of research and development are taken in when needed, to work both time and cost effectively. With a wide network of universities and pharmaceutical companies, promising substances can be in-licensed at an early development phase, develop to clinical phase III and later out-licensed to resourceful pharmaceutical companies for continued phase III development and commercialization. Cyxone’s development portfolio consists of the drug candidates Rabeximod for rheumatoid arthritis (RA) and T20K for multiple sclerosis (MS), with the ambition to investigate whether cyclotides may be efficient for additional autoimmune diseases.
The drug candidate T20K has passed the pre-clinical research phase, which shorten the time to value adding events, such as clinical studies that was initiated in 2019. The properties of T20K shown in cell and animal studies have potential to develop the substance to a breakthrough product to treat MS-patients in different disease stages.
The drug candidate Rabeximod has previously completed a clinical phase IIb study with a confirmed effect and safety profile. It did, however, not achieve a significant effect due to short period of study. A new clinical phase IIb with a longer time period is planned and is expected to start in the beginning of 2020.
Cyxone wishes to have a commercial partner that can enable a faster clinical development to a fully developed drug, which increases the value of the company. Furthermore, Cyxone intends to develop new pharmacologically active cyclotides to use for other immune-related disorders that provide opportunities for long-term value creation and are also open for potential in-license candidates that may be suitable in the company’s development portfolio.